Half Year Financial Review

January 1 – June 30, 2026

The acquisition of Severn on July 1 accelerates the growth of the high performing Process Performance Solutions segment, further increasing its scale and earnings power.

Net sales and Comparable EBITA increased in the second quarter

April–June 2026

- Orders received decreased 10 percent to EUR 1,373 million (EUR 1,520 million). Organically orders received decreased 9 percent. The decrease was mainly driven by capital project order intake in the Biomaterial Solutions and Services segment which decreased from the comparison period but increased sequentially.
- Net sales increased 6 percent to EUR 1,315 million (EUR 1,241 million).
- Comparable EBITA increased 6 percent to EUR 152 million (EUR 143 million). The increase was supported by higher net sales and cost savings from the operating model renewal.
- Comparable EBITA margin remained at the previous year's level at 11.5 percent (11.5%).
- Earnings per share (EPS) increased to EUR 0.40 (EUR 0.15) and adjusted EPS increased to EUR 0.47 (EUR 0.23). The increase in both EPS and adjusted EPS mainly reflects the restructuring expenses related to the operating model renewal in the comparison period.

January–June 2026

- Orders received decreased 14 percent to EUR 2,466 million (EUR 2,852 million). Organically orders received decreased 12 percent.
- Net sales increased 6 percent to EUR 2,560 million (EUR 2,426 million).
- Comparable EBITA remained at the previous year's level and was EUR 266 million (EUR 265 million).
- Comparable EBITA margin was 10.4 percent (10.9%).
- EPS was EUR 0.59 (EUR 0.48). Adjusted EPS was EUR 0.73 (EUR 0.64).
- Cash flow provided by operating activities totaled EUR 100 million (EUR 297 million).

Figures in brackets, unless otherwise stated, refer to the comparison period, i.e., the same period of the previous year.

Key figures[1]

EUR million, or as indicated	Q2/2026	Q2/2025	Change	Q1–Q2/ 2026	Q1–Q2/ 2025	Change
Orders received	**1,373**	1,520	-10%	**2,466**	2,852	-14%
Order backlog[2]				**4,259**	4,711	-10%
Net sales	**1,315**	1,241	6%	**2,560**	2,426	6%
Comparable EBITA	**152**	143	6%	**266**	265	0%
% of net sales	**11.5%**	11.5%	0.0 pp	**10.4%**	10.9%	-0.5 pp
EBITA	**150**	81	86%	**232**	194	19%
Profit for the period	**75**	28	>100%	**109**	89	22%
Earnings per share, EUR	**0.40**	0.15	>100%	**0.59**	0.48	22%
Adjusted earnings per share, EUR	**0.47**	0.23	>100%	**0.73**	0.64	15%
Cash flow provided by operating activities	**65**	79	-18%	**100**	297	-66%
Free cash flow	**50**	46	8%	**68**	240	-72%
Comparable ROCE (LTM)[3]				**13.5%**	13.1%	0.4 pp
ROCE (LTM)[3]				**12.3%**	10.4%	1.9 pp
Net debt to EBITDA[4] ratio (LTM)				**1.42**	1.60	-11%
Gearing[2]				**39%**	42%	-3 pp

1 The calculation of key figures is presented on section 'Formulas for calculation of indicators'.
2 At end of period.
3 Return on capital employed before taxes.
4 Last twelve months' EBITDA

LTM = Last twelve months.

Guidance for 2026 unchanged

Valmet reiterates its guidance issued on February 6, 2026, in which Valmet estimates that net sales in 2026 will remain at the previous year's level in comparison with 2025 (EUR 5,197 million) and Comparable EBITA in 2026 will remain at the previous year's level or increase in comparison with 2025 (EUR 620 million).

Short-term market outlook (July–December 2026)

Valmet's short-term market outlook covers the period July–December 2026, compared with April–June 2026.

It reflects Valmet's estimate of the expected growth rate of its key markets, based on ongoing discussions with customers and other market information.

The outlook describes underlying market trends, excluding the normal seasonal variation in Valmet's business. It should not be interpreted as guidance for Valmet's own orders received.

Process Performance Solutions

Valmet estimates that the market for Process Performance Solutions is expected to remain at low year-over-year growth. At the same time, uncertainty related to the geopolitical situation and global economic outlook remains high, which reduces short-term market visibility.

Biomaterial Solutions and Services

Valmet estimates that the market in Biomaterial Solutions and Services will remain similar to the second quarter. However, it is typical that the timing of customers' large investment decisions can have a significant impact on market activity in any individual quarter. The biomaterial services market is expected to remain soft in the coming quarters. Uncertainty related to the geopolitical situation and global economic outlook remains high, which reduces short-term market visibility.

Segment key figures

Orders received, EUR million	**Q2/2026**	Q2/2025	Change	**Q1–Q2/ 2026**	Q1–Q2/ 2025	Change
Process Performance Solutions	**379**	376	1%	**779**	782	0%
Biomaterial Solutions and Services	**994**	1,144	-13%	**1,687**	2,070	-19%
of which biomaterial services	*493*	*534*	*-8%*	*999*	*1,102*	*-9%*
Total	**1,373**	1,520	-10%	**2,466**	2,852	-14%

Net sales, EUR million	**Q2/2026**	Q2/2025	Change	**Q1–Q2/ 2026**	Q1–Q2/ 2025	Change
Process Performance Solutions	**370**	372	0%	**711**	711	0%
Biomaterial Solutions and Services	**945**	869	9%	**1,849**	1,715	8%
of which biomaterial services	*475*	*460*	*3%*	*889*	*893*	*0%*
Total	**1,315**	1,241	6%	**2,560**	2,426	6%

Comparable EBITA, EUR million	**Q2/2026**	Q2/2025	Change	**Q1–Q2/ 2026**	Q1–Q2/ 2025	Change
Process Performance Solutions	**69**	66	4%	**132**	121	9%
Biomaterial Solutions and Services	**98**	87	12%	**162**	169	-4%
Other	**-15**	-10	-52%	**-28**	-26	-11%
Total	**152**	143	6%	**266**	265	0%

Comparable EBITA, % of net sales	**Q2/2026**	Q2/2025	Change	**Q1–Q2/ 2026**	Q1–Q2/ 2025	Change
Process Performance Solutions	**18.7%**	17.8%	0.9 pp	**18.6%**	17.0%	1.5 pp
Biomaterial Solutions and Services	**10.4%**	10.0%	0.3 pp	**8.8%**	9.9 %	-1.1 pp
Total	**11.5%**	11.5%	0.0 pp	**10.4%**	10.9%	-0.5 pp

EBITA, EUR million	**Q2/2026**	Q2/2025	Change	**Q1–Q2/ 2026**	Q1–Q2/ 2025	Change
Process Performance Solutions	**71**	53	34%	**133**	107	25%
Biomaterial Solutions and Services	**96**	50	90%	**128**	131	-2%
Other	**-16**	-22	27%	**-29**	-43	32%
Total	**150**	81	86%	**232**	194	19%

Net sales and Comparable EBITA increased in the second quarter

"

The Severn acquisition is another step in the systematic development of Valmet's portfolio and it further strengthens the strategic role of the Process Performance Solutions business as an important driver of the Group's growth and profitability. Severn increases the segment's annualized net sales to approximately EUR 1.7 billion.

"In the second quarter of 2026, the decisive actions we took last year to strengthen Valmet's competitiveness continued to deliver — net sales grew organically, and comparable EBITA increased. This came against a market environment that remained cautious overall, though with early indications that capital project activity in our biomaterial businesses is gradually recovering from an unusually subdued start to the year.

Orders received totaled EUR 1.4 billion, with organic order intake down 9 percent against a demanding comparison period. Biomaterial capital orders totaled EUR 501 million, a clear step up from Q1 and consistent with our view of gradually improving capital project activity. Biomaterial services markets remained soft, but the market is stabilizing. Process Performance Solutions delivered organic order growth of 1 percent, in line with the low-growth market environment we described in Q1, including notable wins in the marine segment.

Net sales grew 6 percent organically. Comparable EBITA increased by EUR 9 million year-on-year, supported by higher net sales and cost savings. The comparable EBITA margin was 11.5 percent, flat year-on-year. On a year-to-date basis, comparable EBITA is now slightly ahead of last year, demonstrating the resilience of our full-year trajectory despite the softer start to 2026.

The measures taken to renew Valmet's operating model continue to deliver tangible results. On a last-twelve-months basis, our comparable SG&A costs are now EUR 79 million lower than in the full year 2024. We also continued to implement the production footprint plans we outlined earlier this year.

Shortly after the quarter ended, on 1 July, we closed the Severn acquisition and welcomed approximately 950 new colleagues to Valmet. Severn's offering is a natural complement to ours, and we see a strong cultural fit between our organizations. The acquisition is another step in the systematic development of Valmet's portfolio and further strengthens the strategic role of the Process Performance Solutions business as an important driver of the Group's growth and profitability. Severn expands the segment's addressable market and increases the segment's annualized net sales to approximately EUR 1.7 billion. At this scale, we can respond faster to customers wherever they operate and invest with more conviction in the technology and service capabilities they need.

We are reiterating our guidance for 2026. Looking ahead, geopolitical and macroeconomic uncertainty remains elevated, and customers are likely to remain selective in their investment decisions. With Severn now part of Valmet and the cost discipline we have demonstrated over the past year continuing, we are well positioned to deliver and to keep building a stronger, more resilient Valmet, over the long term."

Thomas Hinnerskov
President and CEO

News conference and webcast for analysts, investors and media

Valmet will host a results webcast in English as a live webcast at https://valmet.events.inderes.com/q2-2026 on Friday, July 24, 2026, at 10:00 a.m. Finnish time (EEST). President and CEO Thomas Hinnerskov and CFO Katri Hokkanen will be presenting the results.

Recording of the webcast will be available shortly after the event on the same address.

Participants may also join the news conference via a conference call by registering at:

https://events.inderes.com/valmet/q2-2026/dial-in
After the registration you will receive dial-in details and a conference ID. To ask a question during the call, please dial #5 on your telephone keypad.

The event is held in English.

Valmet's Half Year Financial Review January 1 – June 30, 2026

Orders received

Orders received, EUR million	Q2/2026	Q2/2025	Change	Organic[1]	Q1–Q2/ 2026	Q1–Q2/ 2025	Change	Organic[1]
Process Performance Solutions	**379**	376	1%	1%	**779**	782	0%	3%
Biomaterial Solutions and Services	**994**	1,144	-13%	-13%	**1,687**	2,070	-19%	-17%
of which biomaterial services	*493*	*534*	*-8%*	-8%	*999*	*1,102*	*-9%*	-8%
Total	**1,373**	1,520	-10%	-9%	**2,466**	2,852	-14%	-12%

1 Organic growth in orders received, excluding impact from changes in foreign exchange rates. Indicative only. The impacts from foreign currency fluctuations are calculated by translating the current-year period's reported key figures into euro amounts using the exchange rates in effect for the comparable period in the previous year.

Orders received in Q2/2026

Orders received decreased 10 percent to EUR 1,373 million (EUR 1,520 million). The decrease was mainly driven by capital project order intake in the Biomaterial Solutions and Services segment which decreased from the comparison period but increased sequentially.

Orders received remained at the previous year's level in the Process Performance Solutions segment and decreased in the Biomaterial Solutions and Services segment.

Organically orders received decreased 9 percent.

In April–June 2026, Valmet received several notable orders, including:

- A board making line, automation and lifecycle support to Sun Paper in China, enabling energy- and resource-efficient production,
- A flue gas condenser and heat pumps for Gren Tartu's biomass heat and power plant in Estonia, and
- An automation order to strengthen Lenzing AG's gas boiler operations in Austria.

Orders received in Q1–Q2/2026

Orders received decreased 14 percent to EUR 2,466 million (EUR 2,852 million) in the first six months.

Orders received remained at the previous year's level in the Process Performance Solutions segment and decreased in the Biomaterial Solutions and Services segment.

Organically orders received decreased 12 percent.

In addition to the aforementioned, in the first six months of 2026, Valmet received several notable orders, including:

- Three additional IntelliTissue machines for Yusen Group in China,
- Valmet integrated automation systems for three new passenger and cargo (RoPax) ships in Finland,
- Automation solutions for a multifuel waste-to-energy plant in Poland,
- Ash Crystallizer helps Mercer Stendal pulp mill in Germany to reduce emissions and improve performance
- A hard nip sizer with supply system and related services to a customer in Europe.

Order backlog

Order backlog, EUR million	**As at June 30, 2026**	As at June 30, 2025	Change	As at March 31, 2026
Total	**4,259**	4,711	-10%	4,200

Order backlog amounted to EUR 4,259 million at the end of the reporting period, which is at the same level as at the end of March 2026 and 10 percent lower than at the end of June 2025.

Approximately 15 percent of the order backlog is from Process Performance Solutions, while 85 percent is from Biomaterial Solutions and Services (at the end of June 2025, 15% and 85%).

Approximately EUR 2.2 billion of the order backlog is currently expected to be realized as net sales during 2026 (at the end of Q2/2025, EUR 2.3 billion was expected to be realized as net sales during 2025).

Long-term development of orders received (EUR million)



LTM = Last Twelve Months

Net sales

Net sales, EUR million	Q2/2026	Q2/2025	Change	Organic[1]	Q1–Q2/ 2026	Q1–Q2/ 2025	Change	Organic[1]
Process Performance Solutions	**370**	372	0%	0%	**711**	711	0%	3%
Biomaterial Solutions and Services	**945**	869	9%	8%	**1,849**	1,715	8%	9%
of which biomaterial services	*475*	*460*	*3%*	*3%*	*889*	*893*	*0%*	*1%*
Total	**1,315**	1,241	6%	6%	**2,560**	2,426	6%	7%

1 Organic growth in net sales. Indicative only. The impacts from foreign currency fluctuations are calculated by translating the current-year period's reported key figures into euro amounts using the exchange rates in effect for the comparable period in the previous year.

Net sales in Q2/2026

Net sales in April–June increased 6 percent to EUR 1,315 million (EUR 1,241 million). Net sales increased in the Biomaterial Solutions and Services segment and remained at the previous year's level in the Process Performance Solutions segment.

Organically net sales increased 6 percent.

Net sales in Q1–Q2/2026

Net sales in the first six months increased 6 percent to EUR 2,560 million (EUR 2,426 million). Net sales increased in the Biomaterial Solutions and Services segment and remained at the previous year's level in the Process Performance Solutions segment.

Organically net sales increased 7 percent.

Long-term development of net sales (EUR million)



LTM = Last twelve months

Organic growth

	Orders received		Net Sales	
	Q2	Q1–Q2	Q2	Q1–Q2
Organic growth[1]	-9%	-12%	6%	7%
Mergers and acquisitions	0%	0%	0%	0%
Changes in foreign exchange rates[2]	-1%	-2%	0%	-2%
Total change	-10%	-14%	6%	6%

1 Indicative only.
2 The impacts from foreign currency fluctuations are calculated by translating the current-year period's reported key figures into euro amounts using the exchange rates in effect for the comparable period in the previous year.

Organic growth in Q2/2026

Organically orders received decreased 9 percent and net sales increased 6 percent in April–June. The decrease was mainly driven by capital project order intake in the Biomaterial Solutions and Services segment which decreased from the comparison period but increased sequentially.

Acquisitions completed in earlier periods did not impact the comparability of orders received or net sales in the second quarter.

Changes in foreign exchange rates compared to the exchange rates for the corresponding period in 2025 decreased orders received by 1 percent and net sales by 0 percent. Foreign exchange rate impacts on orders received were mainly driven by US dollar and Brazilian real, and the impacts on net sales were mainly driven by Brazilian real, US dollar and Chinese yuan.

Organic growth in Q1–Q2/2026

In the first six months, Valmet's orders received decreased organically by 12 percent while net sales increased organically by 7 percent.

Acquisitions completed in earlier periods did not impact the comparability of orders received or net sales in the first six months.

Foreign exchange rate changes decreased Valmet's orders received by 2 percent and net sales by 2 percent. Foreign exchange rate impacts on orders received were mainly driven by US dollar and Swedish krona, and the impacts on net sales were mainly driven by US dollar, Brazilian real and Swedish krona.



Comparable EBITA

Comparable EBITA, EUR million	Q2/2026	Q2/2025	Change	Q1–Q2/ 2026	Q1–Q2/ 2025	Change
Process Performance Solutions	**69**	66	4%	**132**	121	9%
% of net sales	**18.7%**	17.8%	0.9 pp	**18.6%**	17.0%	1.5 pp
Biomaterial Solutions and Services	**98**	87	12%	**162**	169	-4%
% of net sales	**10.4%**	10.0%	0.3 pp	**8.8%**	9.9%	-1.1 pp
Other	**-15**	-10	-52%	**-28**	-26	-11%
Total	**152**	143	6%	**266**	265	0%
% of net sales	**11.5%**	11.5%	0.0 pp	**10.4%**	10.9%	-0.5 pp

Comparable EBITA in Q2/2026

In April–June comparable EBITA increased 6 percent to EUR 152 million, corresponding to 11.5 percent of net sales (EUR 143 million and 11.5%). The increase in comparable EBITA was supported by higher net sales and cost savings from the operating model renewal.

Items affecting comparability amounted to EUR -1 million (EUR -62 million) in the second quarter. The change was mainly related to restructuring expenses of the operating model renewal in the comparison period.

Comparable EBITA of the Process Performance Solutions segment remained at the previous year's level and was EUR 69 million (EUR 66 million). Comparable EBITA margin was 18.7 percent (17.8%). The margin was supported by strong operational performance.

Comparable EBITA of the Biomaterial Solutions and Services segment increased to EUR 98 million, corresponding to 10.4 percent of the segment's net sales (EUR 87 million and 10.0%). Comparable EBITA was supported by higher net sales and cost savings from the operating model renewal.

Comparable EBITA in Q1–Q2/2026

In the first six months Valmet's Comparable EBITA remained at the previous year's level at EUR 266 million, corresponding to 10.4 percent of net sales (EUR 265 million and 10.9%). Despite higher net sales and cost savings from the operating model renewal, margin decreased due to lower gross profit margins.

Items affecting comparability amounted to EUR -34 million (EUR -70 million) in the first six months. The change was mainly related to higher restructuring expenses in the comparison period.

Comparable EBITA of the Process Performance Solutions segment increased 9 percent to EUR 132 million, corresponding to 18.6 percent of the segment's net sales (EUR 121 million and 17.0%). The improvement was supported by cost savings related to the operating model renewal, strong operational performance, and was further supported by elevated product margins during the period.

Comparable EBITA of the Biomaterial Solutions and Services segment remained at the previous year's level EUR 162 million, corresponding to 8.8 percent of the segment's net sales (EUR 169 million and 9.9 percent). Sales mix for the period reflected a higher share of revenue from large projects and smaller mill improvement projects. Profitability declined despite higher net sales and cost savings from the operating model renewal, driven by a lower gross profit margin.

Comparable EBITA margin by segment, Q1-Q2/2026



Comparable EBITA, Q1-Q2/2026 (EUR million)

(excl. Other)



Segments and business areas

Process Performance Solutions segment

Process Performance Solutions delivers flow control technologies and automation systems ranging from individual measurements to full plant-wide solutions, complemented by lifecycle services. It serves a global customer base of broad range of industries with mission-critical solutions that enhance resource efficiency, operational reliability, and financial performance. Its strategic mission is to unlock resource efficiency, with a target EBITA margin of 20% by 2030.

Process Performance Solutions	**Q2/2026**	Q2/2025	Change	**Q1–Q2/ 2026**	Q1–Q2/ 2025	Change
Orders received (EUR million)	**379**	376	1%	**779**	782	0%
Flow Control	208	206	1%	415	421	-1%
Automation Solutions	172	170	1%	364	362	1%
Net sales (EUR million)	**370**	372	0%	**711**	711	0%
Flow Control	206	196	5%	397	388	2%
Automation Solutions	164	176	-6%	315	323	-3%
Comparable EBITA (EUR million)	**69**	66	4%	**132**	121	9%
Comparable EBITA, %	**18.7%**	17.8%	0.9 pp	**18.6%**	17.0%	1.5 pp



Q2/2026

Orders received by the Process Performance Solutions segment remained at the previous year’s level (organically +1%) at EUR 379 million (EUR 376 million). Orders received remained at the previous year's level in both Flow Control and Automation Solutions, demonstrating resilience despite continued geopolitical tensions.

Net sales for the segment remained at the previous year’s level (organically +0%) at EUR 370 million (EUR 372 million). Net sales remained at the previous year's level in Flow Control and decreased in Automation Solutions.

Comparable EBITA of the segment remained at the previous year’s level at EUR 69 million (EUR 66 million). Comparable EBITA margin increased to 18.7 percent (17.8%). The margin was supported by strong operational performance.

The comparable EBITA of the segment corresponded to 41 percent (43%) of Valmet's comparable EBITA (excl. Other).

Q1–Q2/2026

Orders received by the Process Performance Solutions segment remained at the previous year’s level (organically +3%) at EUR 779 million (EUR 782 million) in the first six months. Orders received remained at the previous year's level in both Automation Solutions and Flow Control.

Net sales for the segment remained at the previous year’s level (organically +3%) at EUR 711 million (EUR 711 million). Net sales remained at the previous year's level in both Flow Control and Automation Solutions.

Comparable EBITA of the segment increased to EUR 132 million, corresponding to 18.6 percent of the segment's net sales (EUR 121 million and 17.0%). The improvement was supported by cost savings related to the operating model renewal, strong operational performance, and was further supported by elevated product margins during the period.

The comparable EBITA of the segment corresponded to 45 percent of (42%) Valmet's comparable EBITA (excl. Other).

Orders received by Business area, Q2/2026



Orders received by Business area, Q1–Q2/2026



Long-term development of orders received (EUR million)



Long-term development of comparable EBITA (EUR million) and comparable EBITA margin



LTM = Last twelve months

Biomaterial Solutions and Services segment

Biomaterial Solutions and Services serves global producers across the pulp, paper, packaging, tissue, and bioenergy industries. It provides lifecycle services, upgrades and complete production lines. These solutions enable improvements in fiber yield, energy and water efficiency, emissions, and operational uptime. Its strategic mission is to advance circularity, with a target EBITA margin of 14% by 2030.

Biomaterial Solutions and Services	Q2/2026	Q2/2025	Change	Q1–Q2/ 2026	Q1–Q2/ 2025	Change
Orders received (EUR million)	**994**	1,144	-13%	**1,687**	2,070	-19%
Pulp, Energy and Circularity	436	426	2%	677	871	-22%
Packaging and Paper	340	454	-25%	640	792	-19%
Tissue	218	265	-18%	371	407	-9%
of which biomaterial services	*493*	*534*	*-8%*	*999*	*1,102*	*-9%*
Net sales (EUR million)	**945**	869	9%	**1,849**	1,715	8%
Pulp, Energy and Circularity	411	383	7%	845	705	20%
Packaging and Paper	360	361	0%	695	747	-7%
Tissue	173	125	38%	309	263	17%
of which biomaterial services	*475*	*460*	*3%*	*889*	*893*	*0%*
Comparable EBITA (EUR million)	**98**	87	12%	**162**	169	-4%
Comparable EBITA, %	**10.4%**	10.0%	0.3 pp	**8.8%**	9.9%	-1.1 pp

Q2/2026

Orders received by the Biomaterial Solutions and Services segment decreased 13 percent (organically -13%) to EUR 994 million (EUR 1,144 million). Orders received remained at the previous year's level in the Pulp, Energy and Circularity business area and decreased in the Packaging and Paper and Tissue business areas. The decrease was mainly driven by capital project order intake in the Biomaterial Solutions and Services segment which decreased from the comparison period but increased sequentially. Orders received in biomaterial services decreased 8 percent (-8% organically) to EUR 493 million (EUR 534 million).

Net sales for the segment increased 9 percent (organically +8%) to EUR 945 million (EUR 869 million). Net sales in biomaterial services remained at the previous year's level (organically 3%) at EUR 475 million (EUR 460 million).

Comparable EBITA of the segment increased to EUR 98 million, corresponding to 10.4 percent of the segment's net sales (EUR 87 million and 10.0%). Comparable EBITA was supported by higher net sales and cost savings from the operating model renewal.

The comparable EBITA of the segment corresponded to 59 percent (57%) of Valmet's comparable EBITA (excl. Other).

Q1–Q2/2026

Orders received in the first six months by the Biomaterial Solutions and Services segment decreased 19 percent (organically -17%) to EUR 1,687 million (EUR 2,070 million). Orders received decreased in all three business areas. Orders received in biomaterial services decreased 9 percent (organically -8%) to EUR 999 million (EUR 1,102 million).

Net sales for the segment increased 8 percent (organically +9%) to EUR 1,849 million (EUR 1,715 million). Net sales in biomaterial services remained at the previous year's level (organically +1%) at EUR 889 million (EUR 893 million).

The comparable EBITA of the segment remained at the previous year's level at EUR 162 million, corresponding to 8.8 percent of the segment's net sales (EUR 169 million and 9.9%). Sales mix for the period reflected a higher share of revenue from large projects and smaller mill improvement projects. Profitability declined despite higher net sales and cost savings from the operating model renewal, driven by a lower gross profit margin.

The comparable EBITA of the segment corresponded to 55 percent (58%) of Valmet's comparable EBITA (excl. Other).

Orders received by Business area, Q2/2026



Orders received by Business area, Q1–Q2/2026



Long-term development of orders received (EUR million)



2014–2023 figures have not been restated to reflect the new segment reporting structure which Valmet implemented as of July 1, 2025.

Long-term development of comparable EBITA (EUR million) and comparable EBITA margin



.LTM = Last twelve months

Operating profit

Operating profit (EBIT) in April–June was EUR 127 million corresponding to 9.7 percent of net sales (EUR 57 million and 4.6%). The increase was mainly due to higher restructuring expenses related to the operating model renewal in the comparison period.

Operating profit (EBIT) for the first six months of 2026 was EUR 185 million corresponding to 7.2 percent of net sales (EUR 146 million and 6.0%).

Net financial income and expenses

Net financial income and expenses in April–June were EUR -13 million (EUR -16 million).

Net financial income and expenses in the first six months of 2026 amounted to EUR -26 million (EUR -32 million).

Profit before taxes and earnings per share

Profit before taxes for April–June was EUR 114 million (EUR 41 million). Profit attributable to owners of the parent in April–June was EUR 74 million (EUR 28 million), with EPS at EUR 0.40 (EUR 0.15) and adjusted EPS at EUR 0.47 (EUR 0.23). The increase in both EPS and adjusted EPS mainly reflects the restructuring expenses related to the operating model renewal in the comparison period.

Profit before taxes for the first six months of 2026 was EUR 159 million (EUR 115 million). Profit attributable to owners of the parent was EUR 109 million (EUR 89 million), with EPS at EUR 0.59 (EUR 0.48), and adjusted EPS at EUR 0.73 (EUR 0.64).

Return on capital employed (ROCE) and return on equity (ROE)

For the twelve months preceding June 30, 2026 comparable return on capital employed (comparable ROCE) before taxes was 13.5 percent (13.1%) and return on capital employed (ROCE) before taxes was 12.3 percent (10.4%). Return on equity (ROE) for the corresponding period was 12.3 percent (10.6%).

Cash flow and financing

Operating cash flow

Cash flow provided by operating activities amounted to EUR 65 million (EUR 79 million) in April–June and EUR 100 million (EUR 297 million) in the first six months 2026. The decrease was mainly related to the change in net working capital.

Comparable cash conversion ratio amounted to 62 percent (95%) in the last twelve months. Valmet's average comparable cash conversion ratio for the period 2015–2025 was 92 percent.

Cash conversion ratio—calculated from the reported EBITA—was 67 percent (116%) during the last twelve months. Valmet's average cash conversion ratio for the period 2015–2025 was 97 percent.

Net working capital

Net working capital amounted to EUR 60 million (EUR -139 million) at the end of the reporting period. Net working capital includes a EUR 123 million dividend liability.

The change in net working capital in the statement of cash flows was EUR -70 million (EUR 7 million) in April–June and EUR -153 million (EUR 73 million) in the first six months 2026.

Free cash flow

Free cash flow for April–June amounted to EUR 50 million (EUR 46 million).

Free cash flow for January–June amounted to EUR 68 million (EUR 240 million) the decrease was mainly due to change in net working capital.

Cash flow after investing activities

Net cash provided by investing activities amounted to EUR -15 million (EUR -32 million) in the second quarter.

Cash flow after investing activities totaled 50 million (EUR 48 million) in the second quarter and EUR 71 million (EUR 243 million) in the first six months 2026.

Dividends paid in 2026

In compliance with the resolution of the Annual General Meeting, Valmet paid the first installment of dividend for 2025 on April 9, 2026, totaling EUR 125 million, or EUR 0.68 per share. The second installment of EUR 0.67 per share, totaling EUR 123 million, will be paid in October 2026.

Valmet’s dividend policy is to pay out at least 50 percent of the profit for the period as dividend. The dividend payout ratio for 2025 is 89%.

Debt, gearing and liquidity

At the end of June, net debt to EBITDA ratio was 1.42 (1.60), gearing 39 percent (42%), and equity-to-assets ratio was 42 percent (41%).

Interest-bearing liabilities amounted to EUR 1,580 million (EUR 1,494 million), and net interest-bearing liabilities totaled EUR 965 million (EUR 992 million) at the end of the reporting period.

On December 12, 2025, Valmet completed its first Schuldschein loan transaction, amounting to EUR 375 million. The transaction strengthened Valmet’s long-term debt structure, diversified its funding sources, and expanded Valmet’s debt investor base. The loan consists of 11 tranches with both fixed and floating interest rate structures and offers a diversified maturity profile of three, five, seven and ten years, with an average maturity of nearly six years. By the end of the reporting period, the transaction had been fully drawn, with EUR 281 million settled in December 2025 and the remaining EUR 94 million of the Schuldschein loan settled in January 2026.

The average interest rate of Valmet's total debt was 3.6 percent (3.6%) and average maturity of non-current debt including current installments was 3.5 years (3.1) at the end of June. Lease liabilities have been excluded from calculation of average interest rate and average maturity.

Valmet's liquidity was strong at the end of the reporting period, with cash and cash equivalents amounting to EUR 584 million (EUR 485 million) and other interest-bearing assets totaling EUR 31 million (EUR 18 million). Valmet's liquidity was secured with a committed multi-currency revolving credit facility of EUR 450 million, which was undrawn at the end of the reporting period. Liquidity was additionally secured by an uncommitted commercial paper program worth EUR 300 million, of which EUR 124 million was outstanding at the end of the reporting period.

Valmet's financial targets

Valmet's 2030 financial targets were published on June 4, 2025 and are the following:

- Organic net sales growth (CAGR) over the cycle of 5%
- Comparable EBITA margin of 15%
- Comparable return on capital employed before taxes (Comparable ROCE) of 20%
- Gearing below 50%

Long-term development of key financial indicators

Net sales (EUR million)



Comparable EBITA % of net sales



Comparable return on capital employed before taxes (Comparable ROCE)



Gearing at end of period, %



LTM=Last twelve months.

Capital expenditure

Gross capital expenditure (excluding business combinations and right-of-use assets) totaled EUR 15 million (EUR 33 million) in April–June, and represented 1.1 percent (2.7%) of net sales. Decline reflects the comparison period, which included new modern centralized premises in Finland.

In the first six months of 2026, gross capital expenditure (excluding business combinations and right-of-use assets) totaled EUR 32 million (EUR 57 million), and represented 1.3 percent (2.4%) of net sales.

Acquisitions and divestitures

Valmet made no acquisitions or divestitures during the first six months of 2026.

After the reporting period, on July 1, 2026, Valmet completed the acquisition of Severn Group ("Severn"), a well-established industrial valve company specializing in severe service flow control solutions. The acquisition – originally announced on December 22, 2025 – strengthens the Process Performance Solutions segment and further accelerates Valmet's growth beyond the company's traditional core biomaterials business.

Severn will be integrated into the Flow Control business area of the Process Performance Solutions segment. The acquisition expands Valmet's Flow Control business into new addressable markets, increases the installed base and the related after market potential, and expands the company's technology offering in severe service flow control solutions.

Severn generated net sales of approximately EUR 205 million in 2025, with an EBITA margin of approximately 16 percent. Severn has approximately 950 employees. The transaction is valued at USD 480 million on a cash- and debt-free basis (approximately EUR 410 million calculated at the exchange rates at the time of the announcement in December 2025).

Progress in strategy execution

During the second quarter, Valmet continued to execute its strategy to accelerate growth and improve profitability in the Biomaterial Solutions and Services segment:

As part of the global Commercial Excellence program aimed at accelerating growth in the services business, Valmet has developed new data-driven operating models to improve sales productivity and increase customer activity. Since the launch of the program, proposal response times have been reduced by approximately half, while the number of customer visits has increased by approximately one quarter. At the same time, Valmet has developed new service offerings, identified new lifecycle business opportunities within the installed base, and further developed the commercial pricing of its solutions portfolio.

Under the Global Supply program, significant decisions were made during the first quarter regarding the reorganization of production capacity and consolidation of operations to improve cost-competitiveness. During the second quarter, focus was on the implementation of these measures. The measures will simplify Valmet's manufacturing network, improve efficiency, strengthen competitiveness, and support long-term profitability. The financial benefits of the measures are expected to materialize gradually during 2027–2028. At the same time, procurement efficiency initiatives have progressed as planned, with sourcing shifted to more cost-competitive countries and supplier contract terms renegotiated.

By June 30, 2026, initiatives related to the operational model renewal have decreased last twelve month's comparable SG&A costs by EUR 79 million compared to the base financial year 2024.

Valmet's Executive Leadership Team

Valmet's Executive Leadership Team, as of June 30, 2026, consists of the following members:

- Thomas Hinnerskov, President and CEO
- Katri Hokkanen, CFO
- Emilia Torttila-Miettinen, EVP Automation Solutions
- Simo Sääskilahti, EVP Flow Control
- Petri Rasinmäki, EVP Packaging and Paper
- Sami Riekkola, EVP Pulp, Energy and Circularity
- Jon Jested-Rask, EVP Tissue
- Aki Niemi, EVP Global Supply
- Celso Tacla, EVP Latin America
- Xiangdong Zhu, EVP China Chair
- Anu Pires, EVP People, Communications and Culture
- Olli Hänninen, EVP Strategy and Transformation
- Rasmus Oksala, EVP Legal, and General Counsel

On March 30, 2026 Valmet announced that Valmet's Chief Financial Officer Katri Hokkanen had decided to leave the company. She will continue in her current position to lead Finance and be an active member of Valmet's Executive Leadership team until the end of September 2026 to ensure an orderly and seamless transition. The recruitment process for a new CFO is ongoing.

Personnel

The number of personnel at the end of June was 18,673 (19,412). The decrease mainly reflects the operating model renewal.

During the first six months of 2026, Valmet employed an average of 18,467 people (19,305).

Personnel expenses totaled EUR 689 million (EUR 725 million) in the first six months of 2026, of which wages, salaries and remuneration amounted to EUR 539 million (EUR 568 million). The decrease mainly reflects the operating model renewal.

Personnel	As at June 30, 2026	As at June 30, 2025	Change	As at March 31, 2026
North America	**2,245**	2,355	-5%	2,268
Latin America	**1,669**	1,613	3%	1,630
EMEA	**10,694**	11,366	-6%	10,469
China	**2,293**	2,348	-2%	2,284
Asia-Pacific	**1,772**	1,730	2%	1,719
Total	**18,673**	19,412	-4%	18,370

Geographical areas

Orders received

Measured by orders received, the top three countries in the second quarter of 2026 were the USA, China and Finland, which together accounted for 52 percent of total orders received.

In the first six months of 2026, the top three countries were the USA, China, and Finland, which together accounted for 47 percent of total orders received.

Orders received, EUR million	Q2/2026	Q2/2025	Change	Q1–Q2/ 2026	Q1–Q2/ 2025	Change
North America	**371**	403	-8%	**690**	923	-25%
Latin America	**107**	142	-24%	**225**	261	-14%
EMEA	**449**	575	-22%	**911**	1,042	-13%
China	**303**	294	3%	**407**	399	2%
Asia-Pacific	**143**	107	33%	**233**	227	2%
Total	**1,373**	1,520	-10%	**2,466**	2,852	-14%

Net sales

Measured by net sales, the top three countries in the second quarter of 2026 were the USA, Brazil and China, which together accounted for 49 percent of total net sales. The net sales in Brazil were driven by the Arauco project.

In the first six months of 2026, the top three countries were the USA, Brazil, and China, which together accounted for 51 percent of total net sales.

Net sales, EUR million	Q2/2026	Q2/2025	Change	Q1–Q2/ 2026	Q1–Q2/ 2025	Change
North America	**371**	332	12%	**701**	660	6%
Latin America	**235**	182	29%	**516**	325	59%
EMEA	**441**	455	-3%	**820**	891	-8%
China	**160**	124	29%	**300**	257	17%
Asia-Pacific	**108**	147	-27%	**221**	292	-24%
Total	**1,315**	1,241	6%	**2,560**	2,426	6%

Progress in sustainability

Sustainability strategy

Valmet's sustainability approach is aligned with Valmet's strategy, 'Lead the Way', which puts sustainability in the center of Valmet's operations through a dual mission of unlocking resource efficiency in Process Performance Solutions and advancing circularity in the Biomaterial Solutions and Services.

Valmet's purpose of 'transforming industries towards a regenerative tomorrow' reflects Valmet's ambition and commitment to sustainability. Valmet's Sustainability Agenda translates the purpose into measurable action through four priorities:

- Climate and Nature
- People and Rights
- Responsible Value Chain, and
- Circular and Net-zero Aligned Solutions.

Valmet's Sustainability Agenda helps to guide its customer industries towards a net-zero, circular economy that respects planetary boundaries and protects nature for future generations. Valmet helps industries to shift from linear, fossil-based systems to circular, resource efficient and low carbon operations through circular design, material recovery, energy efficient processes, carbon capture, advanced recycling, and lifecycle services. Equally, sustainability is about how people experience Valmet's business every day.

Valmet's sustainability work is guided by Valmet's Nature and Climate Policy Statement and Human Rights Policy Statement. Valmet's Sustainability team is a part of the global Strategy and Transformation function. This integration supports strong alignment between business strategy, transformation, and sustainability, ensuring an impactful approach.

Valmet's Climate Transition Plan outlines Valmet's pathway toward net-zero and introduces climate targets and decarbonization levers to reduce greenhouse gas (GHG) emissions across its value chain and own operations. Valmet's climate targets are:

- 60 percent emission reduction in own operations by 2030 and net-zero by 2040
- 50 percent share of spend from suppliers with aligned climate targets by 2030
- 60 percent share of net sales from circular and net-zero solutions and services by 2040

Progress in Sustainability Agenda

During the second quarter of 2026, Valmet continued the implementation of its Climate Transition Plan with a focus on actions in own operations. The implementation has started with, for example, creating an e-learning to create internal awareness on the plan, and establishing a net-zero recognition program as well as climate and nature performance indicators for own locations.

Valmet completed a Life Cycle Assessment (LCA) for a lime kiln conversion solution, proving up to 90 percent reduction in GHG emissions. In June, Valmet also introduced new dryer fabric solutions as a part of its Bioneer product family that can reduce the overall carbon footprint of the dryer fabric close to 30 percent according to the LCA.

Valmet progressed with strengthening its sustainability and human rights due diligence by conducting four customer project site assessments covering 28 subcontractors. As a next step, Valmet will continue to drive the identified improvements and corrective actions.

Valmet conducted a new global dialogue survey with an 80% response rate. The survey results indicated good level of belonging and sense of meaning at work. More clear change communication and actioning on feedback were identified as focus areas for improvement.

Progress in health and safety

Valmet's new HSE strategy 'Lead the Way to Zero Harm' sets a vision to reach a world-class health, safety, and environmental performance with an ambitious target to reduce total recordable incident rate to below 1.0 by 2030. The new strategy emphasizes safety as a mindset that must be carried in everyday decision-making. The new HSE strategy is driven by four key pillars: Leadership, Risk Management, Process Excellence and Innovation, and Engagement and Learning.

During the second quarter, the total recordable incident rate (TRIF) for Valmet's own employees was 3.5 (3.0) and for external workforce 5.6 (3.3). The safety observation rate (per million working hours) was 1,592 (1,625).

Lawsuits and claims

On October 15, 2024, Valmet announced that Metsä Fibre Oy has filed a request for arbitration against Valmet Technologies Oy, which is a subsidiary of Valmet. The arbitration concerns Metsä Fibre's bioproduct mill in Kemi, Finland, which came into operation as planned on September 20, 2023.

Valmet Technologies Oy disputes the claims brought by Metsä Fibre and will also actively pursue claims of its own against Metsä Fibre. Metsä Fibre's monetary claims put forward in the arbitration currently amount to approximately EUR 47 million. In addition, Metsä Fibre has also reserved the right to present certain other claims based on contractual relationships between Metsä Fibre and other parties, which are still unresolved. Estimation of the total amount of such claims is not included in the Statement of Claim.

Valmet's management does not expect to the best of its current understanding any material adverse impacts on its operations or financial position due to this arbitration. This assessment takes into account the grounds currently presented, provisions made, insurance coverage in force, and the extent of Valmet's total business activities.

Several lawsuits, claims and disputes based on various grounds are pending against Valmet in various countries, including product liability lawsuits and claims as well as legal disputes related to Valmet's deliveries. Valmet is also a plaintiff in several lawsuits. Although some of the claims are substantial, Valmet's management does not expect to the best of its present understanding that the outcome of these lawsuits, claims and disputes will have a material adverse effect on Valmet in view of the grounds currently presented for them, provisions made, insurance coverage in force and the extent of Valmet's total business activities.

Corporate Governance Statement and Remuneration Report

Valmet has published a Corporate Governance Statement and a Remuneration Report for 2025, which comply with the recommendations of the Finnish Corporate Governance Code for listed companies. These reports also cover other central areas of corporate governance, and they have been published on Valmet's website, separately from the Report of the Board of Directors, at www.valmet.com/governance.

Shares and shareholders

Share capital, number of shares and shareholders

	As at June 30	
	2026	2025
Share capital, EUR	140,000,000	140,000,000
Number of shares	184,529,605	184,529,605
Treasury shares	295,690	317,852
Shares outstanding	184,233,915	184,211,753
Market capitalization, EUR million	3,894	4,848
Number of shareholders	113,492	103,663

Trading of shares

Trading of Valmet shares on Nasdaq Helsinki	January 1–June 30	
	2026	2025
Number of shares traded	52,658,248	49,536,650
Total value, EUR million	1,317	1,304
High, EUR	30.37	30.05
Low, EUR	21.00	21.00
Volume-weighted average price, EUR	25.01	25.44
Closing price on the final day of trading, EUR	21.12	26.27

The closing price of Valmet's share on the final day of trading for the reporting period, June 30, 2026, was EUR 21.12, i.e., 20 percent lower than the closing price on the last day of trading in the second quarter of 2025 (EUR 26.27 on June 30, 2025).

In addition to Nasdaq Helsinki Ltd, Valmet's shares are also traded on other marketplaces, such as CBOE DXE, Turquoise, BATS, Frankfurt and Chi-X. A total of approximately 25 million Valmet shares were traded on these five alternative marketplaces in January–June 2026 (Source: www.valmet.com/investors/valmet-share/trading-volumes/).

Ownership structure as at June 30, 2026



Source: Euroclear Finland Oy

At the end of the reporting period Valmet had 113,492 shareholders according to Euroclear Finland Oy. 45 percent of Valmet's shares were held by Finnish institutions, companies, and foundations; 35 percent by nominee registered and non-Finnish holders, and 21 percent by Finnish private investors.

Flagging notifications

During the reporting period, Valmet did not receive flagging notifications referred to in the Securities Market Act.

More information on flagging notifications can be found at www.valmet.com/flagging-notifications.

Resolutions of Valmet's Annual General Meeting

Valmet's Annual General Meeting 2026 was held in Helsinki on March 25, 2026. The Annual General Meeting adopted the Financial Statements for 2025 and discharged the members of the Board of Directors and the President and CEO from liability for the financial year 2025. The Annual General Meeting adopted the remuneration report for governing bodies, for which the decision is advisory. The Annual General Meeting authorized the Board of Directors to decide on the repurchase of the Company's own shares and on the issuance of shares and special rights entitling to shares.

The Annual General Meeting decided to pay a dividend of EUR 1.35 per share for the financial year which ended on December 31, 2025. The dividend was decided to be paid in two installments. The first installment of EUR 0.68 per share was paid on April 9, 2026, to shareholders who on the dividend record date March 27, 2026, were registered in the Company's shareholders' register held by Euroclear Finland Oy. The second installment of EUR 0.67 per share will be paid on October 7, 2026, to shareholders who on the dividend record date September 29, 2026, are registered in the Company's shareholders' register held by Euroclear Finland Oy.

The Annual General Meeting confirmed the number of Board members as eight and re-elected Pekka Vauramo as Chair of Valmet Oyj's Board and Annika Paasikivi as Vice-Chair. Anu Hämäläinen, Pekka Kemppainen, Annareetta Lumme-Timonen, Monika Maurer, Bernd Eikens and Jonas Gustavsson were re-elected as Board members. The term of office of the members of the Board of Directors expires at the close of the Annual General Meeting 2027.

PricewaterhouseCoopers Oy was re-elected as the Company's auditor for a term expiring at the end of the Annual General Meeting 2027. Pasi Karppinen, Authorised Public Accountant, will act as the responsible auditor. PricewaterhouseCoopers Oy will also carry out the assurance of the Company's sustainability reporting.

Valmet published a stock exchange release on March 25, 2026, concerning the resolutions of the Annual General Meeting and the organizing meeting of the Board of Directors. The stock exchange release and meeting materials can be viewed on Valmet's website at www.valmet.com/investors/governance/annual-general-meeting.

Board authorizations regarding shares

At Valmet's AGM 2026, the Board of Directors was authorized to repurchase up to 9.2 million shares (approximately 5% of all shares) and to issue up to 18.5 million shares (approximately 10% of all shares), including special rights and directed issues. Shares may be repurchased or issued for capital structure management, financing, execution of acquisitions and investments or carrying out other business transactions, and share-based incentives (however, up to 500,000 shares for incentives, corresponding to 0.3% of all shares).

Validity of the authorizations

The authorizations shall remain in force until the close of the next Annual General Meeting, and they cancel the corresponding authorizations granted by the Annual General Meeting 2025.

Use of AGM authorizations

During the second quarter, the authorizations by the Annual General Meeting were not used.

At the end of the reporting period, the Company held 295,690 treasury shares related to the share-based incentive programs, representing roughly 0.16 percent of all Valmet shares.

On March 13, 2026, a total of 5,157 treasury shares were conveyed without consideration to participants in Valmet's long-term incentive plans for the periods 2023–2026.

More information about share-based incentive plans can be found in Valmet's Remuneration Report, which is available at www.valmet.com/governance.

Composition of the Nomination Board

On June 4, 2026, Valmet announced the composition of its Nomination Board. The following persons have been nominated to Valmet's Nomination Board:

- Markus Melkko, President and CEO, Oras Invest Oy (10.40% of share capital and votes)
- Matts Rosenberg, CEO, Solidium Oy (10.10% of share capital and votes)
- Markus Aho, Deputy CEO and Chief Investment Officer, Varma Mutual Pension Insurance Company (3.90% of share capital and votes)
- Mikko Mursula, President and CEO, Ilmarinen Mutual Pension Insurance Company (3.46% of share capital and votes).

Risks and business uncertainties

Valmet is exposed to risks arising from its operations as well as from changes in the global business environment. These risks may have an adverse effect on Valmet's business, financial position, results of operations, and consequently on the value of the company. Valmet seeks to manage and mitigate risks through its risk management processes. Some of the risks faced by Valmet are currently known and assessed, while other risks that are not presently identified or that are not considered material may emerge in the future and become significant.

Geopolitical uncertainty in the Middle East continues due to ongoing military hostilities, including severe disruptions to shipping and energy markets following the closure of the Strait of Hormuz. Valmet has business operations, projects, and personnel in countries in the surrounding region. The situation increases risks related to safety, project execution, logistics, and customer activity, and contributes to cost pressure and volatility in global transport and energy markets. During the reporting period, the Middle East situation had limited impacts on Valmet's operations, whereas related market uncertainty had impacts on customer activity.

Further details of Valmet's risks and business uncertainties are available in the Valmet Annual Report 2025.

Events after the reporting period

July 1, 2026: Valmet completes the acquisition of Severn Group, accelerating the growth of the Process Performance Solutions segment
After the reporting period, on July 1, 2026, Valmet completed the acquisition of Severn Group, an industrial valve company specializing in severe service flow control solutions. The acquisition was originally announced on December 22, 2025.

Severn will be integrated into the Flow Control business area of the Process Performance Solutions segment. Severn generated net sales of approximately EUR 205 million in 2025, with an EBITA margin of approximately 16 percent. Severn has approximately 950 employees. The transaction is valued at USD 480 million on a cash- and debt-free basis (approximately EUR 410 million calculated at the exchange rates at the time of the announcement in December 2025). Additional information is available under the section Acquisitions and Divestments.

There have been no other subsequent events after the reporting period that required recognition or disclosure.

General economic outlook according to OECD

The global economy has come under pressure in the first half of 2026 as the Middle East conflict disrupts energy and commodity markets. Supply chain disruptions through the Strait of Hormuz and damage to Gulf energy facilities have pushed up oil, gas, and fertilizer prices, weighing on confidence and household spending globally. AI investment, lower US tariffs, and supportive policies carried over from 2025, including lower interest rates and elevated public investment, continue to support growth, although financial conditions have tightened and market volatility has risen.

Labor markets are cooling, with job openings falling in several advanced economies. G20 inflation is expected to reach 4.0 percent in 2026 before easing to 3.1 percent in 2027.

Global GDP growth is projected to slow from 3.4 percent in 2025 to 2.8 percent in 2026, and 3.1 percent in 2027. A longer energy shock could cut growth to just 2.1 percent in 2026 and 1.8 percent in 2027. Emerging Asian economies, especially India and parts of Southeast Asia, remain key drivers of global growth.

(OECD Economic Outlook, Volume 2026 Issue 1)

Guidance for 2026 unchanged

Valmet reiterates its guidance issued on February 6, 2026, in which Valmet estimates that net sales in 2026 will remain at the previous year's level in comparison with 2025 (EUR 5,197 million) and Comparable EBITA in 2026 will remain at the previous year's level or increase in comparison with 2025 (EUR 620 million).

Short-term market outlook (July–December 2026)

Valmet's short-term market outlook covers the period July–December 2026, compared with April–June 2026.

It reflects Valmet's estimate of the expected growth rate of its key markets, based on ongoing discussions with customers and other market information.

The outlook describes underlying market trends, excluding the normal seasonal variation in Valmet's business. It should not be interpreted as guidance for Valmet's own orders received.

Process Performance Solutions

Valmet estimates that the market for Process Performance Solutions is expected to remain at low year-over-year growth. At the same time, uncertainty related to the geopolitical situation and global economic outlook remains high, which reduces short-term market visibility.

Biomaterial Solutions and Services

Valmet estimates that the market in Biomaterial Solutions and Services will remain similar to the second quarter. However, it is typical that the timing of customers' large investment decisions can have a significant impact on market activity in any individual quarter. The biomaterial services market is expected to remain soft in the coming quarters. Uncertainty related to the geopolitical situation and global economic outlook remains high, which reduces short-term market visibility.

In Espoo, Finland, on July 23, 2026

Valmet's Board of Directors

Consolidated statement of income

EUR million	Q2/2026	Q2/2025	Q1–Q2/ 2026	Q1–Q2/ 2025
Net sales	**1,315**	1,241	**2,560**	2,426
Cost of goods sold	**-956**	-890	**-1,890**	-1,733
Gross profit	**359**	351	**669**	692
Selling, general and administrative expenses	**-233**	-290	**-463**	-537
Other operating income and expenses, net	**-1**	-6	**-23**	-11
Share in profits and losses of associated companies, operative investments	**2**	1	**2**	1
Operating profit	**127**	57	**185**	146
Financial income and expenses, net	**-13**	-16	**-26**	-32
Profit before taxes	**114**	41	**159**	115
Income taxes	**-40**	-12	**-50**	-26
Profit for the period	**75**	28	**109**	89
Attributable to:				
Owners of the parent	**74**	28	**109**	89
Non-controlling interests	**—**	—	**—**	—
Profit for the period	**75**	28	**109**	89
Earnings per share attributable to owners of the parent:				
Earnings per share, EUR	**0.40**	0.15	**0.59**	0.48
Diluted earnings per share, EUR	**0.40**	0.15	**0.59**	0.48

Consolidated statement of comprehensive income

EUR million	Q2/2026	Q2/2025	Q1–Q2/ 2026	Q1–Q2/ 2025
Profit for the period	**75**	28	**109**	89
Items that may be reclassified to profit or loss:				
Gains and losses on cash flow hedges	**5**	-8	**15**	5
Change in fair value reserve	**—**	-1	**1**	-1
Currency translation on subsidiary net investments	**9**	-63	**30**	-75
Share of other comprehensive income of associated companies accounted for using equity method	**1**	-1	**1**	-1
Income tax relating to items that may be reclassified	**-1**	2	**-3**	-1
Total items that may be reclassified to profit or loss	**14**	-71	**44**	-73
Items that will not be reclassified to profit or loss:				
Remeasurement of defined benefit plans	**-2**	-6	**3**	-1
Income tax relating to items that will not be reclassified	**—**	1	**-1**	—
Total items that will not be reclassified to profit or loss	**-1**	-5	**2**	—
Other comprehensive income for the period	**13**	-76	**46**	-74
Total comprehensive income for the period	**87**	-48	**155**	15
Attributable to:				
Owners of the parent	**87**	-48	**154**	16
Non-controlling interests	**1**	—	**1**	-1
Total comprehensive income for the period	**87**	-48	**155**	15

Consolidated statement of financial position

Assets

EUR million	As at June 30, 2026	As at June 30, 2025	As at December 31, 2025
Non-current assets			
Intangible assets			
Goodwill	**1,804**	1,799	1,800
Other intangible assets	**1,000**	1,079	1,040
Total intangible assets	**2,804**	2,878	2,840
Property, plant and equipment			
Land and water areas	**36**	38	38
Buildings and structures	**162**	159	164
Machinery and equipment	**287**	277	292
Right-of-use assets	**166**	182	171
Assets under construction	**74**	89	75
Total property, plant and equipment	**725**	744	740
Other non-current assets			
Investments in associated companies	**22**	17	19
Non-current financial assets	**31**	48	35
Deferred tax assets	**106**	102	96
Non-current income tax receivables	**7**	41	6
Other non-current assets	**48**	36	46
Total other non-current assets	**215**	244	203
Total non-current assets	**3,744**	3,867	3,782
Current assets			
Inventories			
Materials and supplies	**227**	205	213
Work in progress	**371**	480	377
Finished products	**299**	281	294
Total inventories	**897**	966	884
Receivables and other current assets			
Trade receivables	**828**	712	769
Amounts due from customers under revenue contracts	**288**	349	327
Other current financial assets	**87**	72	82
Income tax receivables	**62**	81	67
Other current assets	**244**	212	189
Cash and cash equivalents	**584**	485	535
Total receivables and other current assets	**2,092**	1,911	1,968
Total current assets	**2,989**	2,877	2,852
Total assets	**6,733**	6,744	6,634

Equity and liabilities

EUR million	**As at June 30, 2026**	As at June 30, 2025	As at December 31, 2025
Equity			
Share capital	**140**	140	140
Reserve for invested unrestricted equity	**1,380**	1,379	1,380
Cumulative translation adjustments	**-82**	-115	-112
Hedge and other reserves	**20**	-2	8
Retained earnings	**1,035**	969	1,168
Equity attributable to owners of the parent	**2,492**	2,371	2,584
Non-controlling interests	**7**	7	6
Total equity	**2,499**	2,378	2,590
Liabilities			
Non-current liabilities			
Non-current debt	**1,063**	1,141	1,153
Non-current lease liabilities	**126**	136	128
Employee benefit liabilities	**149**	160	156
Non-current provisions	**16**	36	20
Other non-current liabilities	**3**	13	7
Deferred tax liabilities	**242**	267	246
Total non-current liabilities	**1,599**	1,753	1,710
Current liabilities			
Current debt	**344**	171	132
Current lease liabilities	**47**	47	48
Trade payables	**460**	414	500
Current provisions	**195**	200	192
Amounts due to customers under revenue contracts	**849**	940	855
Other current financial liabilities	**38**	78	41
Income tax liabilities	**83**	89	58
Other current liabilities	**618**	674	508
Total current liabilities	**2,634**	2,612	2,334
Total liabilities	**4,233**	4,366	4,044
Total equity and liabilities	**6,733**	6,744	6,634

Consolidated statement of cash flows

EUR million	Q2/2026	Q2/2025	Q1–Q2/ 2026	Q1–Q2/ 2025
Cash flows from operating activities				
Profit for the period	**75**	28	**109**	89
Adjustments				
Depreciation and amortization	**51**	52	**102**	106
Change in provisions[2]	**-6**	36	**-2**	42
Financial income and expenses	**13**	16	**26**	32
Income taxes	**40**	12	**50**	26
Other non-cash items	**7**	-9	**28**	11
Change in net working capital	**-70**	7	**-153**	73
Net interests paid	**-12**	-16	**-20**	-27
Income taxes paid	**-32**	-48	**-39**	-55
Net cash provided by (+) / used in (-) operating activities	**65**	79	**100**	297
Cash flows from investing activities				
Capital expenditure on fixed assets	**-15**	-33	**-32**	-57
Proceeds from sale of fixed assets	**—**	2	**3**	2
Business combinations, net of cash acquired and loans repaid	**—**	-1	**—**	1
Net cash provided by (+) / used in (-) investing activities	**-15**	-32	**-29**	-54
Cash flows from financing activities				
Repurchase of own shares	**—**	—	**—**	-3
Dividends paid	**-125**	-125	**-125**	-125
Proceeds from non-current debt[1]	**—**	—	**94**	—
Repayments of current portion of non-current debt[1]	**-13**	-100	**-82**	-127
Repayments of lease liabilities	**-14**	-16	**-28**	-32
Net proceeds from (+) / repayments of (-) current debt	**121**	51	**114**	53
Financial investments	**-19**	33	**-6**	12
Net cash provided by (+) / used in (-) financing activities	**-51**	-157	**-34**	-222
Net increase (+) / decrease (-) in cash and cash equivalents	**-1**	-109	**38**	20
Effect of changes in exchange rates on cash and cash equivalents	**6**	-14	**12**	-18
Cash and cash equivalents at beginning of period	**579**	607	**535**	482
Cash and cash equivalents at end of the period	**584**	485	**584**	485

1 In 2026, Valmet refinanced an existing EUR 50 million loan by entering into a new agreement with the same counterparty. As the refinancing did not involve any cash movements, it is excluded from the Consolidated statement of cash flows.
2 Includes in 2025 EUR 52 million addition to restructuring provision relating to the change negotiations of the operating model renewal.

Consolidated statement of changes in equity

EUR million	Share capital	Reserve for invested unrestricted equity	Cumulative translation adjustments	Hedge and other reserves	Retained earnings	Equity attributable to owners of the parent	Non-controlling interests	Total equity
Balance at January 1, 2026	**140**	**1,380**	**-112**	**8**	**1,168**	**2,584**	**6**	**2,590**
Profit for the period	—	—	—	—	109	**109**	—	**109**
Other comprehensive income for the period	—	—	30	12	4	**46**	—	**46**
Total comprehensive income for the period	—	—	30	12	112	**154**	1	**155**
Transactions with owners in their capacity as owners								
Dividends	—	—	—	—	-249	**-249**	—	**-249**
Share-based payments, net of tax	—	—	—	—	3	**3**	—	**3**
Balance at June 30, 2026	**140**	**1,380**	**-82**	**20**	**1,035**	**2,492**	**7**	**2,499**
Balance at January 1, 2025	140	1,375	-40	-6	1,137	2,607	7	2,614
Profit for the period	—	—	—	—	89	89	—	89
Other comprehensive income for the period	—	—	-75	3	-2	-73	—	-74
Total comprehensive income for the period	—	—	-75	3	88	16	-1	15
Transactions with owners in their capacity as owners								
Dividends	—	—	—	—	-249	-249	—	-249
Repurchase of own shares	—	—	—	—	-3	-3	—	-3
Share-based payments, net of tax	—	4	—	—	-4	1	—	1
Balance at June 30, 2025	140	1,379	-115	-2	969	2,371	7	2,378

Basis of preparation

General information

Valmet Oyj (the “Company” or the “parent company”) and its subsidiaries (together “Valmet”, “Valmet Group” or the “Group”) form a global developer and supplier of technologies, automation, flow control solutions, and services for the process industries.

Valmet Oyj is domiciled in Helsinki, and its registered address is Keilasatama 5, 02150 Espoo, Finland. The Company’s shares are traded on Nasdaq Helsinki Ltd.

These condensed consolidated interim financial statements were approved by the Board of Directors on July 23, 2026.

Basis of presentation

These condensed consolidated interim financial statements for the six months ended June 30, 2026, have been prepared in accordance with IAS 34 – Interim financial reporting and in conformity with IFRS Accounting Standards as adopted by the European Union. The financial information presented in these condensed consolidated interim financial statements has not been audited. These condensed consolidated interim financial statements should be read in conjunction with the Group’s annual consolidated financial statements for the year ended December 31, 2025, which have been prepared in accordance with IFRS.

Valmet Group has applied new standards and interpretations published by IASB that are effective for the first time for financial reporting periods commencing on January 1, 2026. These standards and interpretations did not have a material impact on the results or financial position of the Group, or the presentation of these condensed consolidated interim financial statements.

Except for the above, the accounting policies applied in the preparation of these condensed consolidated interim financial statements are consistent with those followed in the preparation of the Group’s annual consolidated financial statements for the year ended December 31, 2025.

In these condensed consolidated interim financial statements, the figures are presented in million euros subject to rounding, which may cause some rounding inaccuracies in aggregate column and row totals.

IFRS 18 Presentation and disclosure in Financial Statements

Valmet will apply IFRS 18 Presentation and Disclosure in Financial Statements starting from its effective date January 1, 2027 with retrospective application. The comparative information for the financial year ending December 2026 will therefore be restated in accordance with IFRS 18.

IFRS 18 introduces new guidance on the presentation of income and expenses within the Consolidated statement of income, including the use of new categories. As a result, the standard will affect how operating profit is calculated and reported. Based on management’s current assessment and prevailing circumstances, the impact is not expected to be material.

In addition, IFRS 18 amends IAS 7, affecting the presentation of the consolidated statement of cash flows, particularly through the reclassification of cash flows related to interest and dividends. The starting point for determining cash flows from operating activities will shift to operating profit. Valmet does not anticipate any significant changes to the information currently disclosed in the notes. However, to comply with the new disclosure requirements, Valmet will introduce a new note covering Management-defined Performance Measures (MPMs) and provide additional information on operating expenses by nature.

Valmet continues to follow the developing interpretation guidance and analyse the impact of the new standard.

Key exchange rates

	Average rates		Period-end rates	
	Q1–Q2/2026	Q1–Q2/2025	**Q2/2026**	Q2/2025
USD (US dollar)	**1.1673**	1.0920	**1.1394**	1.1720
SEK (Swedish krona)	**10.8100**	11.1374	**11.0935**	11.1465
CNY (Chinese yuan)	**8.0202**	7.9086	**7.7314**	8.3970

Business combinations

Valmet made no acquisitions or divestitures during the first six months of 2026.

Reportable segments

Valmet has two operating segments and two reportable segments for financial reporting purposes: Process Performance Solutions and Biomaterial Solutions and Services. Corporate functions are presented as Other.

The Process Performance Solutions segment delivers flow control technologies and automation systems ranging from individual measurements to full plant-wide solutions, complemented by lifecycle services. The segment serves a global customer base of broad range of industries with mission-critical solutions that enhance resource efficiency, operational reliability, and financial performance. The Biomaterial Solutions and Services segment serves global producers across the pulp, paper, packaging, tissue and bioenergy industries. The segment provides complete production lines and key process islands, complemented by a full range of lifecycle services. These solutions enable improvements in fiber yield, energy and water efficiency, emissions, and operational uptime.

The financial reporting structure reflects Valmet's operational model, and is aligned with the way the Group's Chief Operating Decision Maker (CODM), the President and CEO of Valmet, evaluates the operational performance of the segments and allocates resources. One key indicator of performance reviewed by the CODM is Earnings before interest, taxes and amortization (EBITA). Performance is also assessed through Comparable EBITA, i.e., with EBITA excluding certain items of income and expense that reduce the comparability of Valmet's performance from one period to another. The alternative performance measures of EBITA and Comparable EBITA, are published by Valmet as part of regulated financial information to enable users of the financial information to prepare more meaningful analysis on Valmet's performance. Items affecting comparability consist of income and expenses arising from activities that amend the capacity of Valmet's operations. Items include restructuring costs, gains or losses on sale of businesses or non-current assets, transaction costs related to business combinations, and income and expenses incurred outside Valmet's normal course of business, such as impairment charges and income and expenses recorded as a result of settlement payments to/from third parties (e.g., penalties incurred as a result of tax audits or settlements to closed lawsuits), and share in profits and losses of associated companies.

Orders received, EUR million	Q1–Q2/ 2026	Q1–Q2/ 2025	Change	2025
Process Performance Solutions	**779**	782	0%	1,500
Biomaterial Solutions and Services	**1,687**	2,070	-19%	3,716
Total	**2,466**	2,852	-14%	5,216

Net sales, EUR million	Q1–Q2/ 2026	Q1–Q2/ 2025	Change	2025
Process Performance Solutions	**711**	711	0%	1,481
Biomaterial Solutions and Services	**1,849**	1,715	8%	3,716
Total	**2,560**	2,426	6%	5,197

Comparable EBITA, EUR million	Q1–Q2/ 2026	Q1–Q2/ 2025	Change	2025
Process Performance Solutions	**132**	121	9%	290
Biomaterial Solutions and Services	**162**	169	-4%	381
Other	**-28**	-26	-11%	-51
Total	**266**	265	0%	620

Comparable EBITA, % of net sales	Q1–Q2/ 2026	Q1–Q2/ 2025	2025
Process Performance Solutions	**18.6%**	17.0%	19.6%
Biomaterial Solutions and Services	**8.8%**	9.9%	10.3%
Total	**10.4%**	10.9%	11.9%

EBITA, EUR million	Q1–Q2/ 2026	Q1–Q2/ 2025	Change	2025
Process Performance Solutions	**133**	107	25%	279
Biomaterial Solutions and Services	**128**	131	-2%	323
Other	**-29**	-43	32%	-68
Total	**232**	194	19%	534

EBITA, % of net sales	Q1–Q2/ 2026	Q1–Q2/ 2025	2025
Process Performance Solutions	**18.7%**	15.0%	18.8%
Biomaterial Solutions and Services	**6.9%**	7.6%	8.7%
Total	**9.1%**	8.0%	10.3%

Items affecting comparability, EUR million	Q1–Q2/ 2026	Q1–Q2/ 2025	2025
Process Performance Solutions	**1**	-14	-11
Biomaterial Solutions and Services	**-34**	-39	-58
Other	**-1**	-17	-17
Total	**-34**	-70	-85

Amortization, EUR million	Q1–Q2/ 2026	Q1–Q2/ 2025	Change	2025
Process Performance Solutions	**-26**	-27	4%	-55
Biomaterial Solutions and Services	**-11**	-11	4%	-22
Other	**-10**	-9	-4%	-19
Total	**-47**	-48	2%	-96

Reconciliation between Comparable EBITA, EBITA and Operating profit

EUR million	Q2/2026	Q2/2025	Q1–Q2/ 2026	Q1–Q2/ 2025
Comparable EBITA	**152**	143	**266**	265
Items affecting comparability in cost of sales				
Income and expenses related to capacity adjustments[1,2]	**-5**	-21	**-14**	-22
Expensing of fair value adjustments recognized in business combinations	**—**	—	**-1**	-2
Other items affecting comparability	**-3**	—	**-4**	-1
Items affecting comparability in selling, general and administrative expenses				
Income and expenses related to capacity adjustments[1,2]	**4**	-40	**—**	-43
Expenses related to acquisitions	**-1**	—	**-1**	—
Other items affecting comparability	**-1**	-1	**-1**	-2
Items affecting comparability in other operating income and expenses				
Income and expenses related to capacity adjustments[1]	**3**	—	**-9**	—
Expenses related to acquisitions	**—**	—	**—**	—
Other items affecting comparability	**-1**	—	**-6**	-3
Items affecting comparability in share in profits and losses of associated companies, operative investments				
Other items affecting comparability	**2**	1	**2**	1
EBITA	**150**	81	**232**	194
Amortization included in cost of sales				
Other intangibles	**—**	—	**—**	—
Amortization included in selling, general and administrative expenses				
Intangibles recognized in business combinations	**-17**	-18	**-35**	-36
Other intangibles	**-6**	-6	**-12**	-11
Operating profit	**127**	57	**185**	146

1 Includes EUR 22 million costs in 2026 related to planned changes in Valmet’s manufacturing footprint in Sweden and Poland, of which EUR 11 million relates to restructuring costs.
2 Includes in 2025 EUR 63 million restructuring costs due to change negotiations and strategy renewal costs related to Valmet’s operating model renewal.

Entity-wide information

Valmet has operations globally in approximately 40 countries. Measured by net sales, the top three countries in the first six months of 2026 were the USA, Brazil and China, which together accounted for 51 percent of total net sales. In the first six months of 2025, the top three countries were the USA, China and Brazil, which together accounted for 44 percent of total net sales. Net sales for Finland (the country of domicile) amounted EUR 115 million in the first six months of 2026 (EUR 138 million).

Net sales by destination:

Q1–Q2/2026: EUR 2,560 million

Q1–Q2/2025: EUR 2,426 million

Gross capital expenditure (excluding business combinations and right-of-use assets) by location:

EUR million	North America	Latin America	EMEA	China	Asia-Pacific	Total
Q1–Q2/2026	**5**	**3**	**18**	**4**	**2**	**32**
Q1–Q2/2025	11	2	35	4	4	57

Revenue

Valmet's revenue is reported and monitored by management, by segment, business area and geographical area. Flow Control business area's valves equipment sales are recognized at a point in time. Automation Solutions business area's revenue consists of long-term contracts and short-term service contracts. Revenue for long-term contracts is recognized over time based on the cost-to-cost method. For the projects that do not meet the over time revenue recognition criteria, revenue is recognized at a point in time. Revenue for short-term service contracts is recognized at a point in time. Pulp, Energy and Circularity, Packaging and Paper, and Tissue business areas' revenue is derived from both large long-term projects, for which revenue is mostly recognized over time based on the cost-to-cost method and a large volume of short-term service contracts with relatively low individual value, for which revenue is mainly recognized at a point in time. These short-term service contracts include smaller maintenance, improvements and rebuilds. Sale of spare parts and consumables is recognized at a point in time. The nature of revenue in each geographical area in any given reporting period is driven by volume and size of ongoing projects.

Net sales by business areas:

EUR million	Q2/2026	Q2/2025	Q1–Q2/ 2026	Q1–Q2/ 2025
Flow Control	**206**	196	**397**	388
Automation Solutions	**164**	176	**315**	323
Pulp, Energy and Circularity	**411**	383	**845**	705
Packaging and Paper	**360**	361	**695**	747
Tissue	**173**	125	**309**	263
Total	**1,315**	1,241	**2,560**	2,426

Timing of revenue recognition:

EUR million	Q2/2026	Q2/2025	Q1–Q2/ 2026	Q1–Q2/ 2025
Performance obligations satisfied at a point in time	**715**	704	**1,327**	1,380
Performance obligations satisfied over time	**600**	538	**1,233**	1,046
Total	**1,315**	1,241	**2,560**	2,426

In order to mitigate credit risk and compensate for contract costs incurred upfront, Valmet regularly requires advance payments from its customers. During the reporting period Valmet had not entered into any material contracts where the period between when Valmet transfers a promised good or service to a customer and when the customer pays for that good or service will be one year or more. Neither were there any ongoing projects from previous reporting periods for which the former would apply.

The creditworthiness of a customer is verified before entering into a contract. However, if a risk of non-payment arises after contract inception, the probability of collection of consideration is re-evaluated and if assessed improbable, recognition of revenue is discontinued. An allowance for non-collectability of open receivables and contract assets is established as concluded appropriate.

Valmet receives payments from customers based on invoicing schedules as set out in the customer contracts. Changes in contract assets and liabilities are due to Valmet's performance under the contracts. Amounts due from customers under revenue contracts primarily relate to Valmet's right to consideration for work completed but not yet invoiced at the reporting date. These assets are transferred to trade receivables when right to consideration becomes unconditional, which is typically at the time when Valmet has contractual right to issue an invoice. Significant part of amounts due to customers relate to advance consideration received from customers in long-term capital contracts for which revenue is recognized over time. These amounts are recognized as revenue as (or when) Valmet performs under the contracts.

Following tables provide specification of movements in amounts due from customers under revenue contracts and amounts due to customers under revenue contracts over the reporting period. Revenue recognized in the period also includes revenue recognized related to performance obligations satisfied in previous periods, the amount of which however is insignificant.

Amounts due from customers under revenue contracts:

EUR million	Q1–Q2/ 2026	Q1–Q2/ 2025	2025
Carrying value at beginning of the period	**327**	344	344
Translation differences	**-1**	-2	1
Revenue recognized in the period	**531**	328	936
Transfers to trade receivables	**-570**	-322	-954
Carrying value at end of the period	**288**	349	327

Amounts due to customers under revenue contracts:

EUR million	Q1–Q2/ 2026	Q1–Q2/ 2025	2025
Carrying value at beginning of the period	**855**	904	904
Translation differences	**16**	-34	-29
Revenue recognized in the period	**-1,205**	-1,182	-2,579
Consideration invoiced and/or received	**1,183**	1,251	2,559
Carrying value at end of the period	**849**	940	855

EUR million	As at June 30, 2026	As at June 30, 2025	As at December 31, 2025
Amounts due to customers under revenue contracts for which revenue is recognized			
Point in time	**338**	337	339
Over time	**510**	602	516
Carrying value at end of the period	**849**	940	855

Valmet typically issues contractual product warranties under which it guarantees the mechanical functioning of equipment delivered during the agreed warranty period. Valmet does not issue service-type warranties.

As at June 30, 2026, Valmet had no costs to obtain or fulfill contracts capitalized under IFRS 15.

The aggregate amount of transaction price allocated to unsatisfied or partially satisfied performance obligations as at June 30, 2026, was EUR 4,259 million (EUR 4,711 million).

Net working capital

Payment schedules of large long-term projects have a significant impact on net working capital development. Net working capital does not include non-operative items such as taxes, interest-bearing assets and liabilities, or other items related to funding of the Group's operations.

EUR million	As at June 30, 2026	As at June 30, 2025	As at December 31, 2025	Impact to cash flows Q1–Q2/ 2026
Assets included in net working capital				
Non-current trade receivables	**14**	19	16	**2**
Other non-current assets	**48**	36	46	**-2**
Inventories	**897**	966	884	**-13**
Trade receivables	**828**	712	769	**-58**
Amounts due from customers under revenue contracts	**288**	349	327	**40**
Derivative financial instruments (assets)	**55**	71	63	**8**
Other receivables	**249**	214	190	**-59**
Liabilities included in net working capital				
Employee benefits	**-149**	-160	-156	**-8**
Provisions	**-211**	-237	-212	**-1**
Other non-current non-interest-bearing liabilities	**-1**	-1	-1	**—**
Trade payables	**-460**	-414	-500	**-40**
Amounts due to customers under revenue contracts	**-849**	-940	-855	**-7**
Derivative financial instruments (liabilities)	**-41**	-90	-47	**-6**
Other current liabilities	**-608**	-664	-495	**113**
Total net working capital	**60**	-139	29	**-31**
Effect of changes in foreign exchange rates				**9**
Remeasurement of defined benefit plans				**2**
Change in allowance for doubtful receivables and inventory obsolescence provision				**-13**
Change in provisions				**2**
Dividend liability				**-123**
Change in net working capital in the Consolidated statement of cash flows				**-153**

Intangible assets and property, plant and equipment

Intangible assets

EUR million	Q1–Q2/2026	Q1–Q2/2025	2025
Carrying value at beginning of the period	**2,840**	2,934	2,934
Translation differences	**6**	-24	-22
Capital expenditure	**5**	9	18
Acquired in business combinations	**—**	8	8
Amortization	**-47**	-48	-96
Impairment losses	**—**	-2	-3
Other changes	**—**	1	1
Carrying value at end of the period	**2,804**	2,878	2,840

Property, plant and equipment (excluding right-of-use assets)

EUR million	Q1–Q2/2026	Q1–Q2/2025	2025
Carrying value at beginning of the period	**568**	569	569
Translation differences	**7**	-20	-18
Capital expenditure	**27**	48	85
Depreciation	**-32**	-32	-64
Impairment losses	**-8**	-1	-2
Other changes	**-4**	-2	-2
Carrying value at end of the period	**559**	563	568

Leases

Right-of-use assets

EUR million	Q1–Q2/2026	Q1–Q2/2025	2025
Carrying value at beginning of the period	**171**	156	156
Translation differences	**2**	-6	-5
Additions	**20**	69	82
Depreciation	**-23**	-26	-49
Other changes	**-3**	-12	-14
Carrying value at end of the period	**166**	182	171

Financial instruments

Derivative financial instruments

	As at 30 June, 2026				As at June 30, 2025			
	Notional amount	**Fair value, assets**	**Fair value, liabilities**	**Fair value, net**	Notional amount	Fair value, assets	Fair value, liabilities	Fair value, net
Forward exchange contracts[1]	4,075	51	-39	12	4,007	67	-82	-15
Interest rate swaps[1]	700	3	-1	2	670	3	-6	-3
Electricity forward contracts[2]	163	1	—	1	184	—	-1	—
Nickel forward contracts[3]	462	—	—	—	746	—	-2	-2
Steel scrap forward contracts[3]	1,295	—	—	—	661	—	—	—

1 Notional amount and fair values in EUR million.
2 Notional amount in GWh and fair values in EUR million.
3 Notional amount in metric tons and fair values in EUR million.

The notional amounts give an indication of the volume of derivative contracts entered into, but do not provide an indication of the exposure to risk.

Classification of financial assets and liabilities:

EUR million	As at 30 June, 2026				As at June 30, 2025				
	At amortized cost	At fair value through other comprehensive income	At fair value through profit and loss	Carrying value	At amortized cost	At fair value through other comprehensive income	At fair value through profit and loss	Carrying value	Fair value level
Non-current financial assets									
Equity investments		10	2	**12**		8	2	10	**1,3**
Trade receivables	14			**14**	19			19	
Derivative financial instruments		5	—	**5**		18	—	18	**2**
Total	**14**	**15**	**3**	**31**	19	26	3	48	
Current financial assets									
Interest-bearing financial assets		30		**30**		18		18	**2**
Non-interest-bearing financial assets	6			**6**	2			2	
Trade receivables	828			**828**	712			712	
Derivative financial instruments		40	11	**50**		43	10	52	**2**
Cash and cash equivalents	584			**584**	485			485	
Total	**1,418**	**70**	**11**	**1,498**	1,199	60	10	1,269	
Non-current financial liabilities									
Loans from financial institutions	864			**864**	939			939	
Bonds[1]	199			**199**	202			202	
Lease liabilities	126			**126**	136			136	
Derivative financial instruments		3	—	**3**		12	—	12	**2**
Total	**1,189**	**3**	**—**	**1,192**	1,276	12	—	1,288	
Current financial liabilities									
Loans from financial institutions	199			**199**	99			99	
Lease liabilities	47			**47**	47			47	
Interest-bearing liabilities	146			**146**	72			72	
Trade payables	460			**460**	414			414	
Derivative financial instruments		23	16	**38**		53	25	78	**2**
Total	**851**	**23**	**16**	**890**	632	53	25	710	

1 The bonds have been measured at amortized cost, adjusted by the fair value to the extent that fair value hedge accounting is applied.

For those financial assets and liabilities, which have been recognized at fair value in the Consolidated statement of financial position, the measurement hierarchy and valuation methods described below have been applied.

Level 1

Quoted unadjusted prices at reporting date in active markets. Valmet level 1 financial instruments include equity investments classified as financial assets at fair value through other comprehensive income.

Level 2

The fair value of financial instruments in Level 2 is determined using valuation techniques. These techniques utilize observable market data readily and regularly available. Valmet level 2 financial instruments include over-the-counter (OTC) derivatives classified as financial assets and liabilities at fair value through profit or loss or derivatives qualified for hedge accounting and all other financial assets and liabilities except for equity investments.

Level 3

A financial instrument is categorized into Level 3 if the calculation of the fair value cannot be based on observable market data. Valmet level 3 financial instruments include equity investments classified as financial assets at fair value through profit or loss.

Provisions

EUR million	Q1–Q2/2026	Q1–Q2/2025	2025
Carrying value at beginning of the period	**212**	190	190
Translation differences	**2**	-2	-1
Additions charged to profit or loss[1,2]	**64**	101	190
Acquired in business combinations	**—**	6	6
Provisions used[2]	**-48**	-42	-129
Unused provisions reversed[1,]	**-19**	-17	-44
Carrying value at end of the period	**211**	237	212
Non-current	**16**	36	20
Current	**195**	200	192

1 In 2026, additions charged to profit or loss include a restructuring provision of EUR 12 million related to change negotiations concerning planned changes in Valmet's manufacturing footprint in Sweden and Poland. Reversals of unused provisions recognized in profit and loss amounted to EUR 1 million during 2026.

2 Additions charged to profit or loss include, in the financial year 2025, a restructuring provision of EUR 52 million related to change negotiations for the renewal of the operating model. Of this amount, provisions used totaled EUR 31 million in 2025 and EUR 12 million in 2026.

Contingencies and commitments

EUR million	As at June 30, 2026	As at June 30, 2025	As at December 31, 2025
Guarantees on behalf of Valmet Group	**1,075**	1,070	1,029

The most significant commitments and contingencies of Valmet relate to guarantees provided by Valmet Oyj, its subsidiaries and financial institutions to customers and suppliers in the ordinary course of business, as disclosed in the above table.

On October 15, 2024, Valmet announced that Metsä Fibre Oy has filed a request for arbitration against Valmet Technologies Oy, which is a subsidiary of Valmet. The arbitration concerns Metsä Fibre's bioproduct mill in Kemi, Finland, which came into operation as planned on September 20, 2023.

Valmet Technologies Oy disputes the claims brought by Metsä Fibre and will also actively pursue claims of its own against Metsä Fibre. Metsä Fibre's monetary claims put forward in the arbitration currently amount to approximately EUR 47 million. In addition, Metsä Fibre has also reserved the right to present certain other claims based on contractual relationships between Metsä Fibre and other parties, which are still unresolved. Estimation of the total amount of such claims is not included in the Statement of Claim.

Valmet's management does not expect to the best of its current understanding any material adverse impacts on its operations or financial position due to this arbitration. This assessment takes into account the grounds currently presented, provisions made, insurance coverage in force, and the extent of Valmet's total business activities.

Several lawsuits, claims and disputes based on various grounds are pending against Valmet in various countries, including product liability lawsuits and claims as well as legal disputes related to Valmet's deliveries. Valmet is also a plaintiff in several lawsuits. Although some of the claims are substantial, Valmet's management does not expect to the best of its present understanding that the outcome of these lawsuits, claims and disputes will have a material adverse effect on Valmet in view of the grounds currently presented for them, provisions made, insurance coverage in force and the extent of Valmet's total business activities.

Events after the reporting period

After the reporting period, on July 1, 2026, Valmet completed the acquisition of Severn Group, an industrial valve company specializing in severe service flow control solutions. The acquisition was originally announced on December 22, 2025.

Severn will be integrated into the Flow Control business area of the Process Performance Solutions segment. Severn generated net sales of approximately EUR 205 million in 2025, with an EBITA margin of approximately 16 percent. Severn has approximately 950 employees. The transaction is valued at USD 480 million on a cash- and debt-free basis (approximately EUR 410 million calculated at the exchange rates at the time of the announcement in December 2025).

There have been no other subsequent events after the reporting period that required recognition or disclosure.

Key indicators

	Q1–Q2/2026	Q1–Q2/2025
Comparable return on capital employed (Comparable ROCE) before taxes (LTM), %	**13.5%**	13.1%
Return on capital employed (ROCE) before taxes (LTM), %	**12.3%**	10.4%
Return on equity (ROE) (LTM), %	**12.3%**	10.6%
Net debt to EBITDA[1] ratio	**1.42**	1.60
Gearing, end of period, %	**39%**	42%
Equity to assets ratio, end of period, %	**42%**	41%
Capital employed, end of period, EUR million	**4,079**	3,873
Interest-bearing liabilities, end of period, EUR million	**1,580**	1,494
Net interest-bearing liabilities, end of period, EUR million	**965**	992
Cash conversion ratio (LTM), %	**67%**	116%
Comparable cash conversion ratio (LTM), %	**62%**	95%
Earnings per share, EUR	**0.59**	0.48
Diluted earnings per share, EUR	**0.59**	0.48
Adjusted earnings per share, EUR	**0.73**	0.64
Equity per share, end of period, EUR	**13.53**	12.87
Number of outstanding shares, end of period	**184,233,915**	184,211,753
Average number of outstanding shares	**184,234,874**	184,177,525
Average number of diluted shares	**184,234,874**	184,177,525

1 Last twelve months EBITDA

Formulas for calculation of indicators

In addition to financial performance indicators as defined by IFRS, Valmet publishes certain other widely used measures of performance that can be derived from figures in the Consolidated statement of income and Consolidated statement of financial position, as well as notes thereto. The formulas for calculation of these alternative performance measures are presented below. Some of the alternative performance measures are calculated on a last twelve months basis (LTM).

Comparable gross profit (GP):
Gross profit +/- items affecting comparability in cost of sales

Comparable selling, general and administrative (SG&A) expenses:
Selling, general and administrative expenses +/- items affecting comparability in selling, general and administrative expenses

EBITA:
Operating profit + amortization

Comparable EBITA[1]:
Operating profit + amortization +/- items affecting comparability

Earnings per share:

$$\frac{\text{Profit attributable to shareholders of the Company}}{\text{Average number of shares outstanding during period}}$$

Diluted earnings per share:

$$\frac{\text{Profit attributable to shareholders of the Company}}{\text{Average number of diluted shares during period}}$$

Adjusted earnings per share[1]:

$$\frac{\text{Profit attributable to shareholders of the Company - expensing of fair value adjustments recognized in business combinations, net of tax}}{\text{Average number of shares outstanding during period}}$$

1 Alternative performance measure also calculated on a last twelve months basis

Equity per share:

$$\frac{\text{Equity attributable to owners of the parent}}{\text{Number of outstanding shares at end of period}}$$

Return on equity (ROE), % (LTM):

$$\frac{\text{Profit for the period}}{\text{Total equity (average for period)}} \times 100$$

Return on capital employed (ROCE) before taxes, % (LTM):

$$\frac{\text{Profit before taxes + interest and other financial expenses}}{\text{Total equity + interest-bearing liabilities (average for period)}} \times 100$$

Comparable return on capital employed (ROCE) before taxes, % (LTM):

$$\frac{\text{Profit before taxes + interest and other financial expenses +/- items affecting comparability}}{\text{Total equity + interest-bearing liabilities (average for period)}} \times 100$$

Equity to assets ratio, %:

$$\frac{\text{Total equity}}{\text{Balance sheet total - amounts due to customers under revenue contracts}} \times 100$$

Gearing, %:

$$\frac{\text{Net interest-bearing liabilities}}{\text{Total equity}} \times 100$$

Net interest-bearing liabilities:
Non-current debt + non-current lease liabilities + current debt + current lease liabilities - cash and cash equivalents - other interest-bearing assets

Net debt to EBITDA ratio:

$$\frac{\text{Net interest-bearing liabilities}}{\text{Operating profit + amortization + depreciation (LTM)}}$$

Cash conversion ratio, % (LTM):

$$\frac{\text{Cash flows from operating activities}}{\text{EBITA}} \times 100$$

Comparable cash conversion ratio, % (LTM):

$$\frac{\text{Cash flows from operating activities}}{\text{Comparable EBITA}} \times 100$$

Free cash flow:
Cash flows from operating activities - gross capital expenditure (excl. business combinations and right-of-use assets)

Quarterly information

EUR million, or as indicated	Q2/2026	Q1/2026	Q4/2025	Q3/2025	Q2/2025
Orders received	**1,373**	1,092	1,281	1,083	1,520
Order backlog[1]	**4,259**	4,200	4,306	4,526	4,711
Net sales	**1,315**	1,244	1,477	1,295	1,241
Comparable gross profit	**368**	320	406	355	373
% of net sales	**27.9%**	25.7%	27.5%	27.4%	30.1%
Comparable SG&A expenses	**-235**	-226	-229	-215	-248
% of net sales	**-17.9%**	-18.1%	-15.5%	-16.6%	-20.0%
Comparable EBITA	**152**	114	196	159	143
% of net sales	**11.5%**	9.2%	13.3%	12.3%	11.5%
Operating profit (EBIT)	**127**	58	167	125	57
% of net sales	**9.7%**	4.6%	11.3%	9.7%	4.6%
Profit before taxes	**114**	45	149	112	41
% of net sales	**8.7%**	3.6%	10.1%	8.6%	3.3%
Profit for the period	**75**	34	105	86	28
% of net sales	**5.7%**	2.8%	7.1%	6.6%	2.3%
Earnings per share, EUR	**0.40**	0.19	0.57	0.46	0.15
Adjusted earnings per share, EUR	**0.47**	0.26	0.64	0.54	0.23
Expensing of fair value adjustments recognized in business combinations, net of tax	**-13**	-14	-14	-14	-14
Amortization	**-23**	-24	-24	-24	-24
Depreciation, property, plant and equipment (excl. right-of-use assets)	**-16**	-16	-16	-16	-16
Depreciation, right-of-use assets	**-12**	-12	-11	-12	-12
Depreciation, total	**-28**	-28	-28	-27	-28
Items affecting comparability:					
in cost of goods sold	**-8**	-10	-2	-4	-22
in selling, general and administrative expenses	**2**	-5	-2	-3	-41
in other operating income and expenses, net	**2**	-17	-3	-4	—
in share in profits and losses of associated companies, operative investments	**2**	—	2	1	1
Total items affecting comparability	**-1**	-32	-6	-10	-62
Cash flow provided by operating activities	**65**	35	189	94	79
Gross capital expenditure (excl. business combinations and right-of-use assets)	**-15**	-17	-22	-24	-33
Free cash flow	**50**	18	167	70	46
Business combinations, net of cash acquired and loans repaid	**—**	—	—	—	-1
Research and development expenses, net	**-34**	-32	-34	-29	-32
% of net sales	**-2.5%**	-2.5%	-2.3%	-2.3%	-2.6%

1 At end of period.

Quarterly segment information

Orders received, EUR million	Q2/2026	Q1/2026	Q4/2025	Q3/2025	Q2/2025
Process Performance Solutions	**379**	400	372	345	376
Biomaterial Solutions and Services	**994**	693	908	738	1,144
Total	**1,373**	1,092	1,281	1,083	1,520

Net sales, EUR million	Q2/2026	Q1/2026	Q4/2025	Q3/2025	Q2/2025
Process Performance Solutions	**370**	341	410	361	372
Biomaterial Solutions and Services	**945**	904	1,067	934	869
Total	**1,315**	1,244	1,477	1,295	1,241

Comparable EBITA, EUR million	Q2/2026	Q1/2026	Q4/2025	Q3/2025	Q2/2025
Process Performance Solutions	**69**	63	90	79	66
Biomaterial Solutions and Services	**98**	64	123	89	87
Other	**-15**	-13	-16	-9	-10
Total	**152**	114	196	159	143

Comparable EBITA, % of net sales	Q2/2026	Q1/2026	Q4/2025	Q3/2025	Q2/2025
Process Performance Solutions	**18.7%**	18.5%	21.9%	21.9%	17.8%
Biomaterial Solutions and Services	**10.4%**	7.1%	11.6%	9.5%	10.0%
Total	**11.5%**	9.2%	13.3%	12.3%	11.5%

EBITA, EUR million	Q2/2026	Q1/2026	Q4/2025	Q3/2025	Q2/2025
Process Performance Solutions	**71**	63	92	81	53
Biomaterial Solutions and Services	**96**	32	118	75	50
Other	**-16**	-13	-18	-7	-22
Total	**150**	82	191	149	81

EBITA, % of net sales	Q2/2026	Q1/2026	Q4/2025	Q3/2025	Q2/2025
Process Performance Solutions	**19.1%**	18.4%	22.4%	22.4%	14.2%
Biomaterial Solutions and Services	**10.1%**	3.5%	11.0%	8.0%	5.8%
Total	**11.4%**	6.6%	12.9%	11.5%	6.5%

Items affecting comparability, EUR million	Q2/2026	Q1/2026	Q4/2025	Q3/2025	Q2/2025
Process Performance Solutions	**1**	—	2	2	-14
Biomaterial Solutions and Services	**-2**	-32	-6	-13	-37
Other	**-1**	—	-2	2	-12
Total	**-1**	-32	-6	-10	-62

Amortization, EUR million	Q2/2026	Q1/2026	Q4/2025	Q3/2025	Q2/2025
Process Performance Solutions	**-13**	-14	-14	-14	-14
Biomaterial Solutions and Services	**-5**	-5	-5	-5	-6
Other	**-5**	-5	-5	-5	-5
Total	**-23**	-24	-24	-24	-24

Valmet's Financial reporting in 2026

October 28, 2026 – Interim Review January-September 2026

Valmet Oyj
Keilasatama 5 / PO Box 11
FI-02150 Espoo, Finland
www.valmet.com/investors
www.valmet.com